Business Context and Reporting Period
This Form 8-K Current Report from Lifemd, Inc. (LFMD) covers events occurring on March 16, 2026. The filing primarily addresses significant executive leadership changes within the company's financial and business operations.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data contained herein is limited to executive compensation and transition costs:
- Outgoing CFO Transition Fee: $38,117 per month for a period of six to twelve months.
- New CFO Base Salary: $500,000 annually.
- New CFO Target Bonus: 50% of base salary ($250,000).
- New CFO Equity Grant: 675,000 Restricted Stock Units (RSUs).
Material Changes
The primary material change reported is the departure of the Chief Financial Officer and the appointment of a successor:
- Departure: Marc Benathen resigned as CFO effective March 31, 2026, to pursue a new opportunity. He will forfeit unvested RSUs but retains vested RSUs and will receive COBRA reimbursement through April 1, 2027.
- Appointment: Atul Kavthekar was appointed CFO effective March 16, 2026. He brings experience from Smile America Partners, P3 Health Partners, and Eyecare Partners.
- Other Promotions: Jessica Friedeman was promoted to Chief Business Officer, and Chris Pisano was promoted to Chief Marketing Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or discussion of market risks. Management commentary is limited to the strategic rationale for the leadership changes:
- Transition Plan: The resignation of Mr. Benathen was not due to any disagreement regarding operations or policies. A transition services agreement ensures a smooth handover.
- New Leadership Strategy: Mr. Kavthekar is expected to leverage his background in M&A, capital markets, and healthcare operations to drive growth.
- Equity Vesting Risks: The new CFO's RSUs are subject to forfeiture in the event of a breach of covenants. Time-based vesting accelerates only in cases of termination without "Cause" or resignation for "Good Reason" (pro-rated for less than one year) or upon a "Change of Control."
Investor Verification Checklist
- Verify the full text of the Resignation & Transition Services Agreement (Exhibit 10.1) to confirm the exact duration and total cost of the transition services.
- Review the Employment Agreement (Exhibit 10.2) for specific definitions of "Cause," "Good Reason," and the performance targets required for the 337,500 performance-based RSUs.
- Confirm the impact of the CFO transition on the company's upcoming quarterly earnings call and financial reporting timeline.
- Check the press release (Exhibit 99.1) for additional details on the roles of the newly promoted Chief Business Officer and Chief Marketing Officer.